MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.84

+0.8%

3:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/11/2006 4:28:56 AM
	Read Replies (1) of 2240

GENMAB INITIATES HUMAX-CD20 FRONT LINE CLL STUDY Copenhagen, Denmark; December 11, 2006 – Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of HuMax-CD20™ (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. A total of 56 patients will be enrolled in the study. “Disease progression in patients with advanced CLL is usually rapid and we hope using HuMax-CD20 in combination with FC as first line therapy will result in significant disease improvement for these patients,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. About the trial Patients in this open label study will be randomized into two treatment groups of 28 patients each. Each patient will receive 6 monthly infusions of either 500 or 1000 mg of HuMax-CD20 in combination with FC. Disease status will be measured every 4 weeks until week 24 according to National Cancer Institute Working Group Guidelines and every 3 months thereafter until disease progression or 24 months. Patients not having progressed on their disease at 24 months, will be followed for disease progression at 6 month intervals until 48 months. The objective in the study is to determine the efficacy of HuMax-CD20 in combination with FC in previously untreated CLL patients. The primary endpoint is complete remission measured at any time during the treatment period.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next